Mangoceuticals, Inc. - Common Stock (MGRX)

Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit

DALLAS, TX / ACCESSWIRE / May 23, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, hormone replacement therapies and weight loss is excited to announce that it has engaged renown international performance marketing company, Crakmedia to champion the Company's ongoing creative and digital marketing initiatives.

Mangoceuticals, Inc. (Nasdaq: MGRX), commonly known as MangoRx, is rapidly emerging as a small cap with immense potential in the men's health and wellness sector. The company, operating via a secure telemedicine platform, has been making significant strides in developing, marketing, and selling innovative products, including a unique hair growth formulation named 'GROW' and an ED drug branded 'Mango.'

Mangoceuticals, Inc. (NASDAQ: MGRX) is making significant strides in the men's health and wellness market, positioning itself for a potential surge in share value post-offering. The company's recent public offering, coupled with strategic developments in product expansion and market penetration, particularly in Mexico and Latin America, presents a compelling case for investors and traders.

Mangoceuticals, Inc. (NASDAQ: MGRX), through its subsidiary MangoRx Mexico, is targeting the ED market in Mexico and Latin America, a region with an untapped potential for ED medications. This strategic move, facilitated by Diaz Reus International Law Firm, aims to leverage the over-the-counter availability of other ED drugs. With the introduction of their unique flavored rapid-dissolve tablet, MangoRx seems to be poised to capture a significant share of this market.

Investors frequently seek out stocks with momentum because of the allure of rapid price appreciation. These momentum stocks have a track record of strong price performance, and investors believe that these trends will continue in the short to medium term.

The telehealth market is booming, presenting potentially lucrative opportunities for investors. With a projected CAGR of approximately 18.81% from 2022 to 2030, the global telehealth market is set for significant expansion.

Utilizes AI powered customer segmentation to determine best customers through analysis of 400+ attributes per customer profile

The Dow Jones Industrial Average witnessed a modest increase of 50 points, or 0.1%. Similarly, the S&P 500 and Nasdaq Composite showed minimal changes.

Stocks slipped on Monday as investors questioned whether the market was getting ahead of itself following five straight winning weeks. The Dow Jones Industrial Avershed 60 points, or 0.2%. The S&P 500 lost 0.7%. The Nasdaq Composite declined 1.1% as investors sold Big Technology shares, which have led the market’s gains this year. On a red day, one NASDAQ stock that was up over 10% was Mangoceuticals, Inc. (NASDAQ: MGRX) .

DALLAS, TX / ACCESSWIRE / November 16, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the expansion of its men's health product line with the addition of its hair growth treatment, ‘Grow.'

When we look at emerging players in the pharmaceutical and health sector, a few factors always stand out: innovative products, a strategic business model, impressive partnerships, and powerful marketing initiatives. Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx"), appears to have it all and is set to position itself as a major player in the men’s health and wellness market.

Mangoceuticals, Inc. (NASDAQ:MGRX), colloquially known as MangoRx, is painting an attractive investment picture with its flurry of strategic engagements and partnerships, coupled with a compelling stock market scenario. This Texas-based company is laser-focused on developing, marketing, and selling a variety of men's health and wellness products, including its uniquely formulated drug, "Mango," through a secure telemedicine platform.

In the landscape of promising small-cap investment opportunities, Mangoceuticals, Inc. (NASDAQ:MGRX), a trailblazing telemedicine company targeting men's wellness, is painting an intriguing picture for keen-eyed investors. With its shares currently trading at $1.33, down from its 52-week high of $4.37, MGRX is an enticing buy-low prospect for those bullish on the company's direction and growth.

In the growing market of men's health and wellness, Mangoceuticals, Inc. (NASDAQ: MGRX) is a name that might not yet ring a bell, but certainly will soon. Currently trading at $1.64, this undervalued stock could be poised to take a quantum leap, standing tall with its unique product offerings, targeted marketing, and promising collaborations. All these point towards an innovative, aggressive growth strategy that just might make it the next big thing in the men's health market.

The investment landscape is currently pulsating with a strong and sustained bullish energy. Ordinary folks, known colloquially as Main Street, are increasingly aligning their sentiments with the optimistic view that a looming recession is not on the horizon. The specter of inflation has receded back to the confines of the Federal Reserve's target range and based on the insights from the Fed Funds Futures data from the Chicago Mercantile Exchange (CME), it seems the Fed is girding itself for the final rate increase of this cycle, set to occur later this month.

Mangoceuticals, Inc. (NASDAQ:MGRX), an innovative company dedicated to revolutionizing men’s health and wellness, is making waves in the market with its strategic developments and initiatives. The company’s focus on developing, marketing, and selling men’s health products via a secure telemedicine platform, including their standout medication, “Mango,” places them in a sizable and expanding industry.

ADP jobs data released last week shattered expectations. The private sector added 497,000 jobs in June, well ahead of the 220,000 Dow Jones consensus estimate. It also reversed the decline noted in the previous month. This discrepancy between expectations and the hard data could have profound implications for stocks.

The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market.

DALLAS, TX / ACCESSWIRE / June 29, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is excited to announce its new collaboration with Ice Shaker to supply custom-made Mango-branded Ice Shaker bottles to be sold exclusively on the company's new MakeAmericaHardAgain.com e-commerce portal.

Federal Reserve Chairman Jerome Powell talked tough on inflation Wednesday, saying at a forum that he expects multiple interest rate increases ahead and possibly at an aggressive pace. “We believe there’s more restriction coming,” Powell said during a monetary policy session in Sintra, Portugal. “What’s really driving it ... is a very strong labor market.” The comments reiterate a position taken by Powell’s fellow policymakers at their June meeting, during which they indicated the likelihood of another half percentage point of increases through the end of 2023.

Media Contact Company Name: Investor Brand Media Contact Person: Ash K Email: Send Email Phone: (954) 593-5597 Country: United States Website: https://investorbrandmedia.com/

According to the latest inflation report from the U.S. Bureau of Labor Statistics, the consumer price index experienced a 4% annual increase in May. This reading marks the lowest level observed in over two years. However, economists remain concerned as the "core CPI," which excludes the volatile prices of energy and food, has remained persistently high.The report highlights several categories that have seen notable annual increases, including shelter, motor vehicle insurance, recreation, household furnishings and operations, and new vehicles. On the other hand, certain categories such as airline fares, car and truck rentals, citrus fruits, fresh whole milk, and used cars and trucks have experienced deflation over the past year.

The men's health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men's health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

DALLAS, TX / ACCESSWIRE / May 4, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is pleased to announce the appointment of Amanda Hammer as Chief Operating Officer ("COO").